Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

Cambridge, USA-based biotech Stylus Medicine, which says it is dedicated to developing transformative in vivo genetic ...

Stylus Medicine Inc., a biotechnology company dedicated to developing transformative in vivo genetic medicines, has emerged ...

Stylus Medicine, a startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes ...

Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today announced presentations showcasing its genome engineering ...

RA Ventures, also known as Raven, is a healthcare accelerator for the prominent life sciences venture capital firm. The ...

Stylus Medicine is developing transformative in vivo genetic medicines to unlock cures. Stylus combines engineered recombinases with non-viral delivery to specifically encode therapeutics.